Table 1.
Baseline characteristics of the cohort at second dose of vaccine, according to vaccine schedule and in total
|
Total study cohort (any vaccine) |
BNT162b2 subcohort |
mRNA-1273 subcohort |
ChAdOx1 nCoV-19 subcohort |
ChAdOx1 nCoV-19 and an mRNA vaccine*subcohort |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Vaccinated (n=842 974) | Unvaccinated (n=842 974) | Vaccinated (n=637 107) | Unvaccinated (n=637 107) | Vaccinated (n=76 880) | Unvaccinated (n=76 880) | Vaccinated (n=76 597) | Unvaccinated (n=76 597) | Vaccinated (n=51 766) | Unvaccinated (n=51 766) | ||
| Mean baseline date | May 5, 2021 | May 5, 2021 | April 27, 2021 | April 27, 2021 | May 20, 2021 | May 20, 2021 | June 5, 2021 | June 5, 2021 | May 28, 2021 | May 28, 2021 | |
| Days between doses | 42 (28–45) | .. | 37 (24–42) | .. | 42 (29–42) | .. | 70 (65–82) | .. | 87 (82–97) | .. | |
| Age, years | 52·7 (37·0–67·5) | 52·7 (37·0–67·5) | 54·8 (39·2–68·5) | 54·8 (39·1–68·5) | 41·1 (34·7–61·7) | 48·0 (34·7–61·7) | 64·6 (36·5–71·0) | 64·6 (36·5–71·0) | 35·2 (28·3–43·0) | 35·2 (28·3–43·0) | |
| Male | 342 677 (40·7%) | 342 677 (40·7%) | 263 866 (41·4%) | 263 866 (41·4%) | 34 461 (44·8%) | 34 461 (44·8%) | 30 141 (39·4%) | 30 141 (39·4%) | 13 926 (26·9%) | 13 926 (26·9%) | |
| Female | 500 297 (59·3%) | 500 297 (59·3%) | 373 241 (58·6%) | 373 241 (58·6%) | 42 419 (55·2%) | 42 419 (55·2%) | 46 456 (60·6%) | 46 456 (60·6%) | 37 840 (73·1%) | 37 840 (73·1%) | |
| Homemaker service | 87 004 (10·3%) | 30 680 (3·6%) | 81 704 (12·8%) | 25 718 (4·0%) | 4297 (5·6%) | 1950 (2·5%) | 698 (0·9%) | 2823 (3·7%) | 262 (0·5%) | 174 (0·3%) | |
| Born in Sweden | 703 666 (83·5%) | 578 647 (68·6%) | 533 572 (83·8%) | 442 799 (69·5%) | 63 288 (82·3%) | 50 259 (65·4%) | 64 951 (84·8%) | 50 178 (65·5%) | 41 363 (79·9%) | 35 011 (67·6%) | |
| Education | |||||||||||
| Elementary school, <9 years | 61 022 (7·2%) | 79 375 (9·4%) | 51 598 (8·1%) | 63 360 (9·9%) | 4234 (5·5%) | 6381 (8·3%) | 4420 (5·8%) | 7608 (9·9%) | 737 (1·4%) | 1967 (3·8%) | |
| Elementary school, 9 years | 81 455 (9·7%) | 97 948 (11·6%) | 61 814 (9·7%) | 73 709 (11·6%) | 8309 (10·8%) | 9458 (12·3%) | 6929 (9·1%) | 9084 (11·9%) | 4344 (8·4%) | 5621 (10·9%) | |
| Secondary school, 2 years | 180 672 (21·4%) | 182 971 (21·7%) | 143 917 (22·6%) | 145 325 (22·8%) | 14 824 (19·3%) | 15 810 (20·6%) | 16 391 (21·4%) | 16 065 (21·0%) | 5424 (10·5%) | 5641 (10·9%) | |
| Secondary school, >2 years | 171 349 (20·3%) | 168 922 (20·0%) | 125 590 (19·7%) | 122 362 (19·2%) | 15 848 (20·6%) | 16 511 (21·5%) | 15 669 (20·5%) | 14 927 (19·5%) | 14 117 (27·3%) | 14 982 (28·9%) | |
| University education | 324 660 (38·5%) | 275 444 (32·7%) | 237 148 (37·2%) | 204 663 (32·1%) | 30 503 (39·7%) | 24 708 (32·1%) | 31 973 (41·7%) | 24 994 (32·6%) | 24 770 (47·9%) | 20 893 (40·4%) | |
| Unknown | 23 816 (2·8%) | 38 314 (4·6%) | 17 040 (2·7%) | 27 688 (4·4%) | 3162 (4·1%) | 4012 (5·2%) | 1215 (1·6%) | 3919 (5·1%) | 2374 (4·6%) | 2662 (5·1%) | |
| Comorbidities | |||||||||||
| Myocardial infarction | 21 885 (2·6%) | 18 530 (2·2%) | 18 167 (2·9%) | 15 190 (2·4%) | 1637 (2·1%) | 1335 (1·7%) | 1974 (2·6%) | 1910 (2·5%) | 99 (0·2%) | 86 (0·2%) | |
| Stroke | 29 493 (3·5%) | 16 808 (2·0%) | 26 037 (4·1%) | 13 727 (2·2%) | 1751 (2·3%) | 1185 (1·5%) | 1543 (2·0%) | 1785 (2·3%) | 143 (0·3%) | 101 (0·2%) | |
| Diabetes | 91 203 (10·8%) | 62 198 (7·4%) | 74 361 (11·7%) | 49 614 (7·8%) | 8136 (10·6%) | 4880 (6·4%) | 6944 (9·1%) | 6744 (8·8%) | 1698 (3·3%) | 922 (1·8%) | |
| Hypertension | 262 659 (31·2%) | 207 862 (24·7%) | 212 647 (33·4%) | 170 772 (26·8%) | 21 358 (27·8%) | 15 295 (19·9%) | 24 624 (32·2%) | 19 387 (25·3%) | 3857 (7·5%) | 2281 (4·4%) | |
| Kidney failure | 20 027 (2·4%) | 10 317 (1·2%) | 16 711 (2·6%) | 8481 (1·3%) | 2251 (2·9%) | 706 (0·9%) | 815 (1·1%) | 990 (1·3%) | 242 (0·5%) | 134 (0·3%) | |
| COPD | 17 257 (2·1%) | 13 353 (1·6%) | 14 709 (2·3%) | 10 768 (1·7%) | 1248 (1·6%) | 928 (1·2%) | 1189 (1·6%) | 1563 (2·0%) | 102 (0·2%) | 83 (0·2%) | |
| Asthma | 50 341 (6·0%) | 36 671 (4·4%) | 38 234 (6·0%) | 27 717 (4·4%) | 5118 (6·7%) | 3267 (4·3%) | 3710 (4·8%) | 3254 (4·3%) | 3242 (6·3%) | 2400 (4·6%) | |
| Cancer | 48 512 (5·8%) | 37 092 (4·4%) | 39 720 (6·2%) | 30 696 (4·8%) | 3908 (5·1%) | 2613 (3·4%) | 4225 (5·5%) | 3323 (4·3%) | 635 (1·2%) | 438 (0·9%) | |
| SARS-CoV-2 infection | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Data are median (IQR) or n(%), unless otherwise specified. COPD=chronic obstructive pulmonary disease.
*
Either BNT162b2 or mRNA-1273.